cytochrome c oxidase copper chaperone COX17Genealiases: []
Q-omics provides the consensus-scored COX17 profile across patient tissues and cancer cell-line models. COX17 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, COX17 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, COX17 protein abundance shows 31,594 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight COAD, HNSC, and CCRCC as cancer lineages where COX17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX17 survival associations across molecular data types. COX17 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX17 RNA expression–survival associations across cancer types. High COX17 expression shows unfavorable associations in COAD, KICH, HNSC, GBM and LGG, but favorable associations in MESO. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for COX17 RNA expression.
This table summarizes COX17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COX17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX17 shows higher tumor expression in HNSC, LIHC, BLCA, BRCA, STAD and KIRC. The HNSC box plot shows higher COX17 RNA expression in tumor versus normal tissue (log2 FC = +0.855, t-test p < 0.001).
This table shows molecular features associated with COX17 in patient tissues and cancer cell lines. In patient samples, COX17 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, COX17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Myeloma.
